Clínica e Investigación en Arteriosclerosis (English Edition)最新文献

{"title":"Lipid particle-associated microRNAs with potential to prevent or reduce the development of atherosclerosis in patients with rheumatoid arthritis","authors":"Oriol Alberto Rangel-Zúñiga","doi":"10.1016/j.artere.2025.500825","DOIUrl":"10.1016/j.artere.2025.500825","url":null,"abstract":"","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 3","pages":"Article 500825"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144204386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to achieve LDL cholesterol goals with the funding criteria for new lipid-lowering drugs?","authors":"Antón González-Guerrero ,&nbsp;Elisenda Climent ,&nbsp;David Benaiges ,&nbsp;Juan Pedro Botet","doi":"10.1016/j.artere.2025.500752","DOIUrl":"10.1016/j.artere.2025.500752","url":null,"abstract":"<div><div>Given the apparent inconsistency of having potent lipid-lowering drugs and the unacceptable rate of achievement of therapeutic goals in LDL cholesterol, it is imperative to define new strategies. In this regard, it is appropriate to detail the key points in planning to start lipid-lowering therapy, emphasizing relevant clinical aspects such as the considerable individual variability in the response to statin therapy, positioning in relation to high-potency statins versus statin + ezetimibe combination therapy, and the order of choice of lipid-lowering drugs in the therapeutic strategy. An algorithm is then proposed that ensures a personalized approach to lipid-lowering drug treatment in patients with cardiovascular disease and/or familial hypercholesterolemia with the aim of achieving the therapeutic goal in the shortest possible time, taking into account the patient's previous treatment, the funding criteria for new drugs, and the individualized goal of LDL cholesterol reduction.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 3","pages":"Article 500752"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144204387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma expression of a microRNA panel is differentially associated with 1H-NMR lipoprotein profile in rheumatoid arthritis patients","authors":"Dídac Llop ,&nbsp;Silvia Paredes ,&nbsp;Roser Rosales ,&nbsp;Josep Ribalta ,&nbsp;Joan-Carles Vallvé","doi":"10.1016/j.artere.2025.500759","DOIUrl":"10.1016/j.artere.2025.500759","url":null,"abstract":"<div><h3>Introduction</h3><div>Rheumatoid arthritis (RA) is an autoimmune and inflammatory disorder that leads to cartilage and bone deterioration. This inflammatory activity causes extra-articular manifestations, including the acceleration of the atherosclerotic process. However, the exact causes of this accelerated process are under investigation. In this study, we compared the advanced lipid profile between patients with RA, patients with metabolic disorders, and controls. We also explored how microRNAs previously associated with subclinical atherosclerosis in RA are linked to these lipid subfractions in RA.</div></div><div><h3>Methods</h3><div>The study included 219 patients with RA, 82 with metabolic disorders and 64 controls. Clinical evaluations were performed, and blood samples were collected. Quantification of microRNAs (Let7a, 24, 96, 103, 125a, 125b, 132, 146, 191, 223, 425, 451) and measurement of the advanced lipid profile using nuclear magnetic resonance (NMR) were carried out. Kruskal–Wallis tests and multivariate linear models were applied.</div></div><div><h3>Results</h3><div>Patients with RA exhibited elevated total, large, medium, and small VLDL particles compared to controls. Their LDL subfractions were decreased compared to patients with metabolic disorders, with differences with controls. Patients with RA had fewer and smaller HDL particles than both groups. MicroRNA-125a was associated with VLDL subfractions and small LDL particles. Other microRNAs (96, 132, 191, 451) showed associations with certain LDL subfractions.</div></div><div><h3>Conclusions</h3><div>In patients with RA, elevated levels of VLDL particles have been observed, while LDL levels remain similar to controls. The notable association of microRNA-125a with the metabolism of both VLDL and LDL in RA patients suggests its involvement in lipid regulation. This could point to microRNA-125a as a promising therapeutic target to address the increased cardiovascular risks of RA.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 3","pages":"Article 500759"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144204385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The complexity of cardiovascular risk in women. Descriptive review","authors":"J. Ildefonzo Arocha Rodulfo ,&nbsp;Gestne Aure Fariñez","doi":"10.1016/j.artere.2025.100736","DOIUrl":"10.1016/j.artere.2025.100736","url":null,"abstract":"<div><h3>Objectives</h3><div>Cardiovascular diseases (CVD) are the greatest threat to the health of women and is the leading cause of death amongst women globally; however, cardiovascular disease in women remains understudied, under-recognized, underdiagnosed, and undertreated. The aim of this descriptive review is to summarize the existing problem and to identify the knowledge gaps in cardiovascular disease research, prevention, treatment, and access to care for women.</div></div><div><h3>Material and methods</h3><div>This is a descriptive review of the literature based on numerous articles published in peer-reviewed journals since the beginning of this century related to the spectrum of cardiovascular disease in women.</div></div><div><h3>Results</h3><div>There are several obstacles to improve cardiovascular disease outcomes in women. One of them is the lack of reliable, effective screening modalities since her participation in clinical trial is quite low. Other concern is the complexity of the female organism with several hormonal changes during her life and the hemodynamics stress during pregnancy. Moreover, in the last stage of their life several cardiometabolic risk factor may appear, most of them not recognized by the health team in primary care attention.</div></div><div><h3>Discussion</h3><div>Effective strategies are required to address inequalities in the diagnosis, treatment and prevention of heart disease in women; to advance innovative solutions for early detection and oriented management; to clarify the underlying biological mechanisms that contribute to sex-specific differences in outcomes; and finally, reduce the global burden of cardiovascular disease in women.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 3","pages":"Article 100736"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144204388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"sICAM-1 concentrations are associated with inflammation in contralateral carotid plaque in patients with ischemic stroke","authors":"Núria Puig ,&nbsp;Pol Camps-Renom ,&nbsp;Eduardo Garcia ,&nbsp;Aleyda Benítez-Amaro ,&nbsp;Ana Aguilera-Simón ,&nbsp;Alejandro Fernández-León ,&nbsp;Jose Luis Sanchez Quesada ,&nbsp;Vicenta Llorente-Cortés ,&nbsp;Sonia Benitez","doi":"10.1016/j.artere.2025.100729","DOIUrl":"10.1016/j.artere.2025.100729","url":null,"abstract":"<div><h3>Background</h3><div>Atherosclerotic plaques in the internal carotid artery are responsible for more than 15% of ischemic strokes. Carotid ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET) detects plaque inflammation. Plasma ICAM-1 and LRP1 concentrations have been associated with inflammation in ipsilateral carotid plaque. The aim of the present study was to test the association between the soluble (s) form of these biomarkers and contralateral carotid plaques.</div></div><div><h3>Methods</h3><div>Prospective study conducted in 53 patients with a recent ischemic stroke and at least one atherosclerotic plaque in both carotid arteries. All of the patients underwent an early carotid ¹⁸F-FDG PET, and a blood sample was obtained at 7<!--> <!-->±<!--> <!-->1 days. Several plasma inflammatory markers were evaluated by Multiplex and sLRP1 levels were measured by commercial ELISA. Bivariate and multivariable linear regression was used to assess the association between inflammatory markers and the clinical variables, including contralateral maximum standardized uptake value (SUVmax) and mean SUVmax (mean of contralateral and ipsilateral SUVmax) of ¹⁸F-FDG uptake. Hazard ratio (HR) was estimated with Cox models adjusted for potential confounding factors to evaluate recurrence.</div></div><div><h3>Results</h3><div>Multivariable linear regression analysis showed an independent association between sICAM-1 and sVCAM-1 and mean SUVmax (CI<!--> <!-->=<!--> <!-->−0.064–0.325, <em>p</em> <!-->=<!--> <!-->0.004; CI<!--> <!-->=<!--> <!-->0.079–0.554, <em>p</em> <!-->=<!--> <!-->0.010). In addition, in bivariate regression analysis, sICAM-1 was associated with contralateral SUVmax (CI<!--> <!-->=<!--> <!-->0.049–0.382, <em>p</em> <!-->=<!--> <!-->0.012). Cox regression showed that mean SUVmax was associated with stroke recurrence (HR<!--> <!-->=<!--> <!-->5.604, <em>p</em> <!-->=<!--> <!-->0.044).</div></div><div><h3>Conclusions</h3><div>sICAM-1 was independently associated with mean carotid plaque inflammation and with inflammation in contralateral plaque. sICAM-1 could be an indicator of plaque inflammation even in asymptomatic plaques.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 2","pages":"Article 100729"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143835224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PCSK9 inhibitors tug of war: Compliance, adverse events and LDL-cholesterol target","authors":"Francesco Sbrana,&nbsp;Beatrice Dal Pino","doi":"10.1016/j.artere.2025.500771","DOIUrl":"10.1016/j.artere.2025.500771","url":null,"abstract":"","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 2","pages":"Article 500771"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional habits in patients with peripheral arterial disease: Adherence to the Mediterranean diet","authors":"Elena Vilalta Doñate ,&nbsp;Francisca García Fernández ,&nbsp;Salvador Martínez Meléndez ,&nbsp;Consuelo Castillo Castillo ,&nbsp;Pablo Salas Medina ,&nbsp;Isabel Almodóvar Fernández","doi":"10.1016/j.artere.2025.100726","DOIUrl":"10.1016/j.artere.2025.100726","url":null,"abstract":"<div><h3>Introduction</h3><div>Adherence to the Mediterranean diet (Dietmed) exerts protective effects on cardiovascular disease (CVD). In the Lower Extremity Peripheral Arterial Disease (PAD) there are fewer studies that analyze these data.</div></div><div><h3>Objective</h3><div>To determine adherence to Dietmed and dietary habits in patients with PAD, according to a history of CVD (coronary and/or cerebral ischaemic pathology) and according to the ankle-brachial index (ABI ≥ or &lt; 0,5).</div></div><div><h3>Material and methods</h3><div>Cross-sectional analytical study carried out in a tertiary hospital. The sample was collected consecutively. Sociodemographic and clinical history, ankle-brachial index (ABI) and a 14-point Dietmed adherence dietary questionnaire were included. The analysis of categorical variables was carried out using the Pearson’s Chi-Square test, the T-Student’s statistic test for independent samples was used for parametric variables and the U. Mann-Whitney test for non-parametric variables.</div></div><div><h3>Results</h3><div>Of the 97 patients, 87,6% had low adherence to Dietmed, with no differences according to the severity of PAD. However, when we analysed the data according to whether or not they had a history of CVD, we observed a high adherence to some items included in Dietmed, specifically, in the CVD group, the consumption of lean meat (95,5% vs 64%; p = 0.004). In addition, we observed a significant difference in the consumption in the group without a history of CVD (32% vs 9,1%; p = 0.033).</div></div><div><h3>Conclusion</h3><div>In our population, patients with PAD, regardless of the stage of the disease and whether they had associated coronary or cerebral ischaemic pathology, had low adherence to Dietmed. Therefore, it is important to implement nutritional education programmes in patients with PAD in all stages, as well as in those patients who have already suffered a vascular event, so that they maintain adherence to healthy dietary habits in the long term.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 2","pages":"Article 100726"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polygenic risk and subclinical atherosclerosis in asymptomatic middle-aged individuals. The ILERVAS study","authors":"Emilio Ortega ,&nbsp;Amanda Jiménez ,&nbsp;Sheila López-Ruiz ,&nbsp;Eva Castro-Boqué ,&nbsp;José Manuel Valdivielso ,&nbsp;Marcelino Bermúdez-López ,&nbsp;Gemma Chiva-Blanch","doi":"10.1016/j.artere.2025.100751","DOIUrl":"10.1016/j.artere.2025.100751","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>More than 50% of first cardiovascular events (CVE) occur in populations identified as at low or intermediate risk by the risk equations, so the inclusion of additional variables, such as polygenic risk scores (PRS), has been proposed to improve the predictive capacity of these equations. The aim of this study was to assess whether a PRS, independently or with clinical risk equations, is associated with the presence, severity and extent of subclinical atherosclerosis.</div></div><div><h3>Methods</h3><div>109 subjects with atherosclerosis were selected from the ILERVAS cohort (primary prevention) and matched with 109 participants without atherosclerosis of the same age, sex and SCORE2 risk level. Atherosclerosis was assessed and quantified by arterial wall vascular ultrasound in 12 territories, and PRS was estimated using the Cardio inCode Score®. The predictive capacity of the presence of subclinical atherosclerosis was estimated, as well as the association between the extent and severity of atherosclerosis with PRS and clinical risk (SCORE2).</div></div><div><h3>Results</h3><div>PRS was similar between participants with or without atherosclerosis (<em>P</em> = .525). We did not find an association between PRS and SCORE2 (r = −.29, <em>P</em> = .709), and the addition of PRS to SCORE2 did not improve the prediction of atherosclerosis [AUC (95% CI) = .566 (.477, .654, <em>P</em> = .148). The extent of atherosclerosis was related to SCORE2 (<em>P</em> = .009), but not to PRS (<em>P</em> = .709).</div></div><div><h3>Conclusions</h3><div>The Selected PRS is not associated with the presence of atherosclerosis or clinical risk, suggesting that its additional contribution to CVE risk would be mediated by mechanisms independent of the development of atherosclerosis. Additional biomarkers are needed to improve the prediction of subclinical atherosclerosis without using imaging tests as a first step in personalised assessment.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 2","pages":"Article 100751"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143835235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular vesicles in atherosclerosis: Current and forthcoming impact.","authors":"José A. Páramo ,&nbsp;Ana Cenarro ,&nbsp;Fernando Civeira ,&nbsp;Carmen Roncal","doi":"10.1016/j.artere.2025.100718","DOIUrl":"10.1016/j.artere.2025.100718","url":null,"abstract":"<div><div>Atherosclerosis is the main pathogenic substrate for cardiovascular diseases (CVDs). Initially categorized as a passive cholesterol storage disease, nowadays, it is considered an active process, identifying inflammation among the key players for its initiation and progression. Despite these advances, patients with CVDs are still at high risk of thrombotic events and death, urging to deepen into the molecular mechanisms underlying atherogenesis, and to identify novel diagnosis and prognosis biomarkers for their stratification. In this context, extracellular vesicles (EVs) have been postulated as an alternative in search of novel biomarkers in atherosclerotic diseases, as well as to investigate the crosstalk between the cells participating in the processes leading to arterial remodelling. EVs are nanosized lipidic particles released by most cell types in physiological and pathological conditions, that enclose lipids, proteins, and nucleic acids from parental cells reflecting their activation status. First considered cellular waste disposal systems, at present, EVs have been recognized as active effectors in a myriad of cellular processes, and as potential diagnosis and prognosis biomarkers also in CVDs. This review summarizes the role of EVs as potential biomarkers of CVDs, and their involvement into the processes leading to atherosclerosis.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 2","pages":"Article 100718"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated plasma levels of TNF-R1 predict the development of acute ischemic events in coronary patients with diabetes","authors":"Sebastián Mas-Fontao ,&nbsp;Nieves Tarín ,&nbsp;Carmen Cristóbal ,&nbsp;Manuel Soto-Catalán ,&nbsp;Ana Pello ,&nbsp;Alvaro Aceña ,&nbsp;Jairo Lumpuy-Castillo ,&nbsp;Carmen Garces ,&nbsp;Carmen Gomez-Guerrero ,&nbsp;Carlos Gutiérrez-Landaluce ,&nbsp;Luis M. Blanco-Colio ,&nbsp;José Luis Martín-Ventura ,&nbsp;Ana Huelmos ,&nbsp;Joaquín Alonso ,&nbsp;Lorenzo López Bescós ,&nbsp;Juan A. Moreno ,&nbsp;Ignacio Mahíllo-Fernández ,&nbsp;Óscar Lorenzo ,&nbsp;María Luisa González-Casaus ,&nbsp;Jesús Egido ,&nbsp;José Tuñón","doi":"10.1016/j.artere.2025.100735","DOIUrl":"10.1016/j.artere.2025.100735","url":null,"abstract":"<div><h3>Objectives</h3><div>To examine the relationship between inflammatory biomarkers and the occurrence of cardiovascular events in patients with type 2 diabetes mellitus (DM2) and stable coronary artery disease.</div></div><div><h3>Methods</h3><div>A total of 964 patients with stable coronary artery disease were included. Plasma levels of inflammatory markers, including tumour necrosis factor receptors 1 and 2 (TNF-R1 and TNF-R2), growth differentiation factor-15 (GDF-15), soluble suppression of tumorigenicity 2 (sST2), and high-sensitivity C-reactive protein (hsCRP) were measured. The primary endpoint was the development of acute ischaemic events (any type of acute coronary syndrome, stroke, or transient ischaemic attack).</div></div><div><h3>Results</h3><div>There were 232 diabetic patients and 732 non-diabetic patients. Patients with coronary artery disease and DM2 (232, 24%) had higher levels of TNF-R1, TNF-R2, GDF-15, sST2 (p &lt; .001), and hsCRP compared to patients without DM2, indicating a higher inflammatory state. After a median follow-up of 5.39 (2.81–6.92) years, patients with DM2 more frequently developed the primary endpoint (15.9% vs 10.8%; p = .035). Plasma levels of TNF-R1 were independent predictors of the primary endpoint in patients with DM2, along with male gender, triglyceride levels, and the absence of treatment with angiotensin-converting enzyme inhibitors. None of these inflammatory markers predicted the development of this event in non-diabetic patients.</div></div><div><h3>Conclusions</h3><div>Patients with stable coronary artery disease and DM2 exhibit elevated levels of the proinflammatory markers TNF-R1, TNF-R2, GDF-15, and sST2. Moreover, TNF-R1 is an independent predictor of acute ischaemic events only in diabetic patients.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 2","pages":"Article 100735"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143835225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}